RxDoctor Payments Data

Charles Sweeney, MD

Ophthalmology · Lake City, FLNPI 1316922669

Payments from drug & device makers

$1,797in general payments, 2019–2025

Across 47 payments — averaging $38.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$481
  • Carl Zeiss Meditec, Inc.$400
  • Harrow Eye, LLC$125
  • Bausch & Lomb Americas Inc.$118
  • Notal Vision, Inc.$117
  • Tarsus Pharmaceuticals, Inc.$99
  • plus $457 from 11 others

What the payments were for

  • Consulting fees$40022%
  • Food & beverage$1,38077%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,797 in reported general payments places this provider in the 45th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$139,546
Medicare patients
538
Services billed
1,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine14$10,620
RhopressaNetarsudil Mesylate11$6,856
VyzultaLatanoprostene Bunod12$4,486
RocklatanNetarsudil Mesylat/Latanoprost13$4,222
Prednisolone Acetate84$3,091
Latanoprost308$2,669
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$1,270
ValacyclovirValacyclovir Hcl18$1,155
Tobramycin-DexamethasoneTobramycin/Dexamethasone25$1,130
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat76$1,080
ErythromycinErythromycin Base70$1,066
Fluorometholone12$1,018
Brimonidine Tartrate61$886
Doxycycline Hyclate18$882
Dorzolamide Hcl34$637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$90$10,62014 claims
Bausch & Lomb Americas Inc.Vyzulta$118$4,48612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Lake City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →